Patients who DO NOT need Supplemental Oxygen

NIRMATRELVIR with RITONAVIR is recommended as an option for treating COVID-19 in adults, only if they:

Do not need supplemental oxygen for COVID-19 and

have an increased risk for progression to severe COVID-19, as defined in the independent advisory group report commissioned by the Department of Health and Social Care.

**Please review interactions and contraindications carefully**

SOTROVIMAB is recommended as an option for treating COVID-19 in adults and young people aged 12 years and over and weighing at least 40 kg, only if:

They do not need supplemental oxygen for COVID-19 and

they have an increased risk for progression to severe COVID-19, as defined in the independent advisory group report commissioned by the Department of Health and Social Care and nirmatrelvir plus ritonavir is contraindicated or unsuitable.

Remdesivir, Molnupiravir – these medications have a conditional recommendation from NICE.

Please review NICE guidelines and consider individual patient characteristics before prescribing.